- Home
- Companies
- Emergent BioSolutions Inc.
- Products
- Model ACAM2000 - Virus Smallpox Vaccine
Model ACAM2000 - Virus Smallpox Vaccine
ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) is a live, vaccinia virus smallpox vaccine licensed in the U.S. by the Food and Drug Administration for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. It was developed under a contract with the U.S. Centers for Disease Control and Prevention (CDC).
ACAM2000 vaccine was developed to be a licensed smallpox vaccine manufactured using modern cell-culture techniques complying with current Good Manufacturing Practice standards- Production of first-generation vaccines ceased in the early 1980s following a successful smallpox vaccination campaign by the World Health Organization that led to the declared eradication of smallpox in 1980.
Today, ACAM2000 vaccine is the primary smallpox vaccine designated for use in a bioterrorism emergency and forms the majority of the U.S. Government`s smallpox vaccine stockpile. More than 200 million doses of ACAM2000 have been supplied to the US Government for its Strategic National Stockpile and has also been supplied under an FDA Investigational New Drug application to several other governments around the world-